Current concepts in tall stature and overgrowth syndromes

S. L S Drop, N. Greggio, M. Cappa, S. Bernasconi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In this overview an update is given on the pathogenesis, classification and differential diagnosis of overgrowth syndromes. In addition, height prognosis and therapeutic modalities available for managing mainly constitutional tall stature are discussed. Constitutional tall stature comprises normal variants in which one or both parents are tall. Primary disorders may have a prenatal onset and may be of chromosomal or genetic origin. Secondary overgrowth syndromes are most often the result of hormonal disturbances. Height prediction plays a key role in the management of tall children. Prediction equation models have been developed based on the growth data of healthy tall children. There is general agreement that a favourable effect on reducing ultimate height is obtained using high doses of sex steroids (girls 100-300 μg ethinyloestradiol; boys testosterone (T) ester depot preparations 250-1000 mg/month), the height reduction being greater when the treatment is started at a lower chronological and/or bone age. An alternative is the induction of puberty with low doses of sex steroids (girls 5-50 μg ethinyloestradiol; boys T esters 25-50 mg/m2/3 wk). In addition orthopaedic procedures have been suggested, but there is limited experience. Although psychosocial factors constitute the main reason for treating tall stature, extensive psychological investigations before or during height limiting therapy are lacking. Moreover, there are no objective data indicating lifelong psychosocial damage resulting from being tall.

Original languageEnglish
Pages (from-to)975-984
Number of pages10
JournalJournal of Pediatric Endocrinology and Metabolism
Volume14
Issue numberSUPPL. 2
Publication statusPublished - 2001

Fingerprint

Ethinyl Estradiol
Esters
Steroids
Psychology
Orthopedic Procedures
Delayed-Action Preparations
Puberty
Testosterone
Differential Diagnosis
Therapeutics
Parents
Bone and Bones
Growth

Keywords

  • Androgen therapy
  • Consensus guidelines
  • Growth hormone
  • Oestrogen therapy
  • Overgrowth syndromes
  • Tall stature

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Drop, S. L. S., Greggio, N., Cappa, M., & Bernasconi, S. (2001). Current concepts in tall stature and overgrowth syndromes. Journal of Pediatric Endocrinology and Metabolism, 14(SUPPL. 2), 975-984.

Current concepts in tall stature and overgrowth syndromes. / Drop, S. L S; Greggio, N.; Cappa, M.; Bernasconi, S.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 14, No. SUPPL. 2, 2001, p. 975-984.

Research output: Contribution to journalArticle

Drop, SLS, Greggio, N, Cappa, M & Bernasconi, S 2001, 'Current concepts in tall stature and overgrowth syndromes', Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. SUPPL. 2, pp. 975-984.
Drop, S. L S ; Greggio, N. ; Cappa, M. ; Bernasconi, S. / Current concepts in tall stature and overgrowth syndromes. In: Journal of Pediatric Endocrinology and Metabolism. 2001 ; Vol. 14, No. SUPPL. 2. pp. 975-984.
@article{57d6c0cbde774b9c8c302386cba63113,
title = "Current concepts in tall stature and overgrowth syndromes",
abstract = "In this overview an update is given on the pathogenesis, classification and differential diagnosis of overgrowth syndromes. In addition, height prognosis and therapeutic modalities available for managing mainly constitutional tall stature are discussed. Constitutional tall stature comprises normal variants in which one or both parents are tall. Primary disorders may have a prenatal onset and may be of chromosomal or genetic origin. Secondary overgrowth syndromes are most often the result of hormonal disturbances. Height prediction plays a key role in the management of tall children. Prediction equation models have been developed based on the growth data of healthy tall children. There is general agreement that a favourable effect on reducing ultimate height is obtained using high doses of sex steroids (girls 100-300 μg ethinyloestradiol; boys testosterone (T) ester depot preparations 250-1000 mg/month), the height reduction being greater when the treatment is started at a lower chronological and/or bone age. An alternative is the induction of puberty with low doses of sex steroids (girls 5-50 μg ethinyloestradiol; boys T esters 25-50 mg/m2/3 wk). In addition orthopaedic procedures have been suggested, but there is limited experience. Although psychosocial factors constitute the main reason for treating tall stature, extensive psychological investigations before or during height limiting therapy are lacking. Moreover, there are no objective data indicating lifelong psychosocial damage resulting from being tall.",
keywords = "Androgen therapy, Consensus guidelines, Growth hormone, Oestrogen therapy, Overgrowth syndromes, Tall stature",
author = "Drop, {S. L S} and N. Greggio and M. Cappa and S. Bernasconi",
year = "2001",
language = "English",
volume = "14",
pages = "975--984",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Current concepts in tall stature and overgrowth syndromes

AU - Drop, S. L S

AU - Greggio, N.

AU - Cappa, M.

AU - Bernasconi, S.

PY - 2001

Y1 - 2001

N2 - In this overview an update is given on the pathogenesis, classification and differential diagnosis of overgrowth syndromes. In addition, height prognosis and therapeutic modalities available for managing mainly constitutional tall stature are discussed. Constitutional tall stature comprises normal variants in which one or both parents are tall. Primary disorders may have a prenatal onset and may be of chromosomal or genetic origin. Secondary overgrowth syndromes are most often the result of hormonal disturbances. Height prediction plays a key role in the management of tall children. Prediction equation models have been developed based on the growth data of healthy tall children. There is general agreement that a favourable effect on reducing ultimate height is obtained using high doses of sex steroids (girls 100-300 μg ethinyloestradiol; boys testosterone (T) ester depot preparations 250-1000 mg/month), the height reduction being greater when the treatment is started at a lower chronological and/or bone age. An alternative is the induction of puberty with low doses of sex steroids (girls 5-50 μg ethinyloestradiol; boys T esters 25-50 mg/m2/3 wk). In addition orthopaedic procedures have been suggested, but there is limited experience. Although psychosocial factors constitute the main reason for treating tall stature, extensive psychological investigations before or during height limiting therapy are lacking. Moreover, there are no objective data indicating lifelong psychosocial damage resulting from being tall.

AB - In this overview an update is given on the pathogenesis, classification and differential diagnosis of overgrowth syndromes. In addition, height prognosis and therapeutic modalities available for managing mainly constitutional tall stature are discussed. Constitutional tall stature comprises normal variants in which one or both parents are tall. Primary disorders may have a prenatal onset and may be of chromosomal or genetic origin. Secondary overgrowth syndromes are most often the result of hormonal disturbances. Height prediction plays a key role in the management of tall children. Prediction equation models have been developed based on the growth data of healthy tall children. There is general agreement that a favourable effect on reducing ultimate height is obtained using high doses of sex steroids (girls 100-300 μg ethinyloestradiol; boys testosterone (T) ester depot preparations 250-1000 mg/month), the height reduction being greater when the treatment is started at a lower chronological and/or bone age. An alternative is the induction of puberty with low doses of sex steroids (girls 5-50 μg ethinyloestradiol; boys T esters 25-50 mg/m2/3 wk). In addition orthopaedic procedures have been suggested, but there is limited experience. Although psychosocial factors constitute the main reason for treating tall stature, extensive psychological investigations before or during height limiting therapy are lacking. Moreover, there are no objective data indicating lifelong psychosocial damage resulting from being tall.

KW - Androgen therapy

KW - Consensus guidelines

KW - Growth hormone

KW - Oestrogen therapy

KW - Overgrowth syndromes

KW - Tall stature

UR - http://www.scopus.com/inward/record.url?scp=0034884542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034884542&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 975

EP - 984

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - SUPPL. 2

ER -